Scholarlink

Background <p>Chronic wounds are a heterogeneous group of disorders characterized by persistent ischemia, chronic inflammation, immune dysregulation, and impaired tissue regeneration. These conditions lead to delayed healing and substantial clinical and socioeconomic burden. Owing to their complex and multifactorial pathophysiology, therapeutic strategies targeting single molecular pathways show limited efficacy, highlighting the need for integrated regenerative approaches.</p> Area covered <p>In this review, we summarize the current research developments in mesenchymal stem cell (MSC)–based therapeutics for chronic wound healing. We also address the biological mechanisms underlying MSC therapeutic effects, cell source selection, autologous versus allogeneic strategies, delivery and biomaterial-assisted approaches, extracellular vesicle (EV)–based therapies, engineering strategies, in vivo tracking technologies, and key challenges in clinical translation, manufacturing, and regulatory development.</p> Expert opinion <p>Although MSC-based therapies have demonstrated substantial regenerative potential in preclinical studies, their clinical translation for chronic wound healing remains challenging because of heterogeneous cell sources, lack of standardized manufacturing processes, and insufficient mechanism-linked potency assays. The continued perception of MSCs as empirical cell-based products rather than dynamic, microenvironment-responsive therapeutic systems remains a critical limitation. As highlighted in this review, MSC efficacy is predominantly influenced by secretome-mediated paracrine signaling. This underscores the need for mechanism-informed and indication-specific development strategies. Emerging approaches such as biomaterial-assisted delivery, preconditioning, and EV-based therapies offer opportunities to improve reproducibility and scalability. However, successful translation requires robust quality control, standardized product definitions, and good manufacturing practice (GMP)-compliant manufacturing frameworks. It is pivotal to establish MSCs as reliable and programmable therapeutic modalities for chronic wound management to bridge biological complexity with standardized pharmaceutical control.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mesenchymal stem cell-based therapeutics for chronic wound healing: from biological potential to programmable pharmaceutical modalities

  • 期刊论文

  • 发表日期：

    2026年7月8日

查看全文
  • Kyeong Eun Kim,
  • Byeol Yoon,
  • Yoo Kyung Kang

摘要

Background

Chronic wounds are a heterogeneous group of disorders characterized by persistent ischemia, chronic inflammation, immune dysregulation, and impaired tissue regeneration. These conditions lead to delayed healing and substantial clinical and socioeconomic burden. Owing to their complex and multifactorial pathophysiology, therapeutic strategies targeting single molecular pathways show limited efficacy, highlighting the need for integrated regenerative approaches.

Area covered

In this review, we summarize the current research developments in mesenchymal stem cell (MSC)–based therapeutics for chronic wound healing. We also address the biological mechanisms underlying MSC therapeutic effects, cell source selection, autologous versus allogeneic strategies, delivery and biomaterial-assisted approaches, extracellular vesicle (EV)–based therapies, engineering strategies, in vivo tracking technologies, and key challenges in clinical translation, manufacturing, and regulatory development.

Expert opinion

Although MSC-based therapies have demonstrated substantial regenerative potential in preclinical studies, their clinical translation for chronic wound healing remains challenging because of heterogeneous cell sources, lack of standardized manufacturing processes, and insufficient mechanism-linked potency assays. The continued perception of MSCs as empirical cell-based products rather than dynamic, microenvironment-responsive therapeutic systems remains a critical limitation. As highlighted in this review, MSC efficacy is predominantly influenced by secretome-mediated paracrine signaling. This underscores the need for mechanism-informed and indication-specific development strategies. Emerging approaches such as biomaterial-assisted delivery, preconditioning, and EV-based therapies offer opportunities to improve reproducibility and scalability. However, successful translation requires robust quality control, standardized product definitions, and good manufacturing practice (GMP)-compliant manufacturing frameworks. It is pivotal to establish MSCs as reliable and programmable therapeutic modalities for chronic wound management to bridge biological complexity with standardized pharmaceutical control.